InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (INFU) Financial Performance & Income Statement Overview
Analyze InfuSystem Holdings, Inc. (INFU) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
InfuSystem Holdings, Inc. (INFU) Income Statement & Financial Overview
View the income breakdown for InfuSystem Holdings, Inc. INFU across both annual and quarterly reports.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $36.002M | $34.72M | $33.85M | $35.32M |
| Cost of Revenue | $16.13M | $15.55M | $15.63M | $16.27M |
| Gross Profit | $19.87M | $19.17M | $18.22M | $19.05M |
| Gross Profit Ratio | $0.55 | $0.55 | $0.54 | $0.54 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $16.34M | $18.55M | $15.35M | $15.53M |
| Operating Expenses | $16.34M | $18.55M | $15.60M | $15.78M |
| Total Costs & Expenses | $32.47M | $34.10M | $31.23M | $32.05M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$373000.00 | -$336000.00 | $361000.00 | $476000.00 |
| Depreciation & Amortization | $0.00 | $3.32M | $3.42M | $3.15M |
| EBITDA | $3.78M | $3.91M | $6.05M | $6.41M |
| EBITDA Ratio | $0.10 | $0.11 | $0.18 | $0.18 |
| Operating Income | $3.78M | $618000.00 | $2.62M | $3.27M |
| Operating Income Ratio | $0.10 | $0.02 | $0.08 | $0.09 |
| Other Income/Expenses (Net) | -$331000.00 | -$365000.00 | -$352000.00 | -$480000.00 |
| Income Before Tax | $3.45M | $253000.00 | $2.26M | $2.79M |
| Income Before Tax Ratio | $0.10 | $0.007 | $0.07 | $0.08 |
| Income Tax Expense | -$847000.00 | -$520000.00 | $1.33M | -$1.79M |
| Net Income | $4.29M | -$267000.00 | $933000.00 | $1.81M |
| Net Income Ratio | $0.12 | -$0.008 | $0.03 | $0.05 |
| EPS | $0.12 | -$0.01 | $0.04 | $0.08 |
| Diluted EPS | $0.12 | -$0.01 | $0.04 | $0.08 |
| Weighted Avg Shares Outstanding | $20.97M | $21.13M | $21.27M | $21.29M |
| Weighted Avg Shares Outstanding (Diluted) | $21.29M | $21.13M | $21.71M | $21.71M |
Financial performance has remained strong, with revenue growing from $35.32M in Q3 2024 to $36.002M in Q2 2025. Gross profit continued to perform well, with margins at 55% in the latest quarter. Operating income reached $3.78M in Q2 2025, holding a steady 10% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $3.78M. Net income rose to $4.29M, keeping EPS at $0.12. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan